Preclinical work has demonstrated that tumor cell proliferation in breast cancer is significantly driven by upregulation of the cyclin D–CDK4/6-axis [18,19], and CDK4/6-inhibitors induce cytostasis through cell-cycle arrest in the G1 phase leading to in-growth inhibition. Here, CDK4 is linked to neoplasm.